Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version January 2019
Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version January 2019
复制标题
DOI：
10.1007/s00347-019-0906-2
复制
发表时间：
2020-01-01
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
LUXTURNA™于2018年11月23日在欧盟获批用于治疗双等位基因RPE65突变且有足够存活视网膜细胞的患者的视网膜营养不良。以下文章介绍了根据德国视网膜学会、德国眼科学会和德国眼科医生专业协会达成的共识制定的LUXTURNA™(诺华，瑞士巴塞尔)的治疗建议。
Luxturna™ was approved in the European Union for the treatment of retinal dystrophy in patients with biallelic RPE65 mutations and sufficient viable retinal cells on 23 November 2018. The following article presents the treatment recommendations for Luxturna™(Novartis, Basel, Switzerland) formulated on the basis of a consensus between the German Retina Society, the German Ophthalmological Society, and the German Professional Association of Ophthalmologists.